Bottom line
In ATTAIN-MAINTAIN, adults previously treated with tirzepatide (Zepbound) or semaglutide (Wegovy) maintained substantially more of their prior weight reduction when switched to daily oral orforglipron — now FDA-approved and marketed as Foundayo — than when switched to placebo. The trial supports an injectable-to-oral maintenance option, but it did not compare switching with simply continuing the original injectable medication.
Why this study matters
The maintenance phase is a clinically challenging issue in modern obesity medicine. Patients may achieve substantial weight reduction with injectable treatment but later want a simpler regimen, run into access problems, or prefer to avoid indefinite injections. ATTAIN-MAINTAIN directly tested whether continued pharmacologic treatment with an oral GLP-1 could preserve prior benefit.
What ATTAIN-MAINTAIN studied
This double-blind Phase 3b trial enrolled 376 adults who had previously completed the SURMOUNT-5 head-to-head trial of tirzepatide versus semaglutide and had reached a weight plateau. Participants were re-randomized 3:2 to once-daily oral orforglipron (titrated to a maximum tolerated dose of 24 or 36 mg) or placebo for 52 weeks, alongside diet and physical activity. Results were published in Nature Medicine in May 2026.
What the trial found
Among participants previously treated with tirzepatide, orforglipron maintained an estimated 74.7% of the previous weight reduction, compared with 49.2% with placebo. Among those previously treated with semaglutide, the corresponding estimates were 79.3% and 37.6%. Put differently, participants who switched from semaglutide to orforglipron gave back only about 1 kg on average over the year, and those who switched from tirzepatide about 5 kg — far less than those switched to placebo. Gastrointestinal effects were the most common treatment-related adverse events, and discontinuations for adverse events were low.
What the trial does not prove
- It did not compare switching to orforglipron with continuing tirzepatide or semaglutide.
- It does not establish the best maintenance dose or duration for every patient.
- It does not prove that every patient should transition from an injectable to an oral medication.
- Follow-up was one year; longer-term comparative maintenance data remain important.
BeLite Clinical Perspective
The practical lesson is that maintenance should be individualized for each patient. The study broadens the maintenance framework: continued treatment does not necessarily mean indefinite continuation of the identical drug and route used during active weight loss.
Frequently asked questions
Does this mean I should stop Wegovy or Zepbound and switch to orforglipron?
No. A patient doing well on an effective, tolerated regimen may have no reason to switch. ATTAIN-MAINTAIN tested one maintenance strategy against placebo, not against continued injectable therapy.
Did patients keep all of their previous weight loss?
No. On average, orforglipron preserved substantially more prior weight reduction than placebo, but not necessarily all of it — particularly after tirzepatide, the more potent injectable.
Is orforglipron an oral peptide?
No. It is a small-molecule, nonpeptide oral GLP-1 receptor agonist, marketed as Foundayo.
What is the key clinical question now?
Which patients benefit most from continuing an injectable, lowering the dose, extending the interval, or transitioning to an oral maintenance regimen.
References
- Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. doi:10.1038/s41591-026-04386-7. https://www.nature.com/articles/s41591-026-04386-7
- Eli Lilly. Topline ATTAIN-MAINTAIN results (press release), December 18, 2025.
- FDA. Foundayo (orforglipron) approval announcement, April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
About BeLite Medical Center
BeLite Medical Center in Northern, VA helps you reach your weight loss goals.
